Table 2.
Univariate and multivariate-Cox regression analyses of prognostic factors in hepatocellular carcinoma patients treated by transarterial chemoembolization in the training cohort
|
Variable
|
Univariate analysis
|
Multivariate analysis
|
Score
|
|||||
|
Before first TACE
|
Hazard ratio
|
95%CI
|
P
value
|
Hazard ratio
|
95%CI
|
P
value
|
B
|
|
| Age (yr), < 60/≥ 60 | 0.781 | 0.324-1.012 | 0.124 | |||||
| Sex, male/female | 0.891 | 0.456-1.213 | 0.211 | |||||
| HBsAg status, positive/negative | 0.671 | 0.319-0.987 | 0.121 | |||||
| Child-Pugh class, A/B | 1.178 | 0.614-1.418 | 0.256 | |||||
| Largest tumor size (cm), < 5/≥ 5 | 1.619 | 1.671-2.341 | 0.005 | 1.312 | 0.981-1.992 | < 0.001 | 0.4168 | 1 |
| Tumor number, solitary/multiple | 1.987 | 1.561-2.354 | 0.007 | 1.289 | 1.481-2.002 | < 0.001 | 0.3178 | 1 |
| BCLC stage, A/B | 1.671 | 1.319-1.987 | <0.001 | 1.789 | 1.289-2.112 | < 0.001 | 0.4288 | 1 |
| AFP (IU/mL), < 200/≥ 200 | 0.678 | 0.214-1.018 | 0.128 | |||||
| ECOG performance status score, 0/1/2 | 1.102 | 0.781-1.456 | 0.199 | |||||
| AST (U/L), < 40/≥ 40 | 0.543 | 0.178-0.967 | 0.089 | |||||
| Irregular tumor margin, absent/present | 1.562 | 1.211-1.897 | < 0.001 | 1.457 | 1.090-2.089 | < 0.001 | 0.404 | 1 |
| Capsule, absent/present | 1.432 | 1.121-1.976 | 0.032 | 1.321 | 1.007-1.764 | 0.082 | ||
The regression coefficients (B) in multivariate-Cox regression analysis were multiplied by 2 and rounded to calculate the clinical score. The clinical model used the median value (2) of total score (4) to stratify patients into high and low-risk group. HCC: Hepatocellular carcinoma; TACE, Transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; AST: Aspartate aminotransferase; AFP: Alpha fetoprotein; ECOG: Eastern Cooperative Oncology Group; CI: Confidence interval.